Lyndra aims to fundamentally change the way patients take medicines through the development of oral, ultra-long-acting, sustained release oral therapies that drastically improve healthcare outcomes. The Lyndra platform was developed at the Massachusetts Institute of Technology, in the laboratory of Dr. Robert Langer in collaboration with the Bill and Melinda Gates Foundation. Lyndra formulations transform medications taken daily or more frequently into a weekly or monthly dose, promising to improve patient adherence as well as to optimize the pharmacokinetic profile of the dosage form.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/13/17 | $23,000,000 | Series A |
GF Securities Healthlink Capital Partners Healthcare Polaris Partners  Quark Venture Suffolk Equity Yonghua Capital | undisclosed |
| 01/29/19 | $55,000,000 | Series B |
Bill & Melinda Gates Foundation GF Securities Gilead Sciences Healthlink Capital HOPU Investments Invus Orient Life Partners Healthcare Polaris Partners Quark Venture Suffolk Equity Yonghua Capital | undisclosed |
| 12/21/23 | $101,000,000 | Series E |
Polaris Partners Sarissa Capital Sun Pharmaceutical Industries | undisclosed |
